Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NephroDI Therapeutics Enters Agreement to Develop a First-in-Class Treatment for a Genetic, Rare Disease of the Kidneys","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by NephroDI Therapeutics

    Menu

    NephroDI Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              NephroDI Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NephroDI Therapeutics Enters Agreement to Develop a First-in-Class Treatment for a Genetic, Rare Disease of the Kidneys

              Details:

              The agreement aims for the clinical development of NephroDI’s asset, NDI-5001, a novel kidney-targeted small molecule AMPK activator, as a potential therapy for X-linked congenital Nephrogenic Diabetes Insipidus (NDI).

              Lead Product(s): NDI-5001

              Therapeutic Area: Rare Diseases and Disorders Product Name: NDI-5001

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: McQuade Center for Strategic Research and Development

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NephroDI Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease

              Details:

              NephroDI’s lead product, NDI-5033 is a unique adenosine monophosphate activated kinase (AMPK) activator that can stimulate water reabsorption without causing hypoglycemia, decreasing overall urine output.

              Lead Product(s): NDI-5033

              Therapeutic Area: Genetic Disease Product Name: NDI-5033

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Xontogeny, LLC

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing May 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY